Overload stack (strongest)
Hexarelin + CJC-1295 (no DAC)
3.600.000 ₫
Vial-by-vial breakdown
The maximum-output GH-axis stack. Hexarelin is the most potent GHRP characterised in published human work — producing a GH spike 2–3× larger than GHRP-6 and substantially larger than Ipamorelin at equivalent doses. CJC-1295 (no DAC) is paired specifically because its short ~30-min half-life keeps the GHRH signal pulsatile, preserving the synergistic spike rather than blunting it through tonic stimulation. The trade-off is real and disclosed: at sustained high doses Hexarelin produces a measurable rise in cortisol and prolactin, and the GHSR receptor desensitises after roughly 14–16 weeks of continuous use — which is why this stack is positioned for 8–12 week blocks rather than indefinite use. Dosed nightly. The combined effect has been shown to lift IGF-1 by ~78% in clinical work.
Dosage
Start CJC-1295 (no DAC) 50 mcg + Hexarelin 50 mcg once nightly; after 1 week double to 100 mcg of each nightly, in 8–12 week blocks (10mg / 5mg are vial sizes, not doses)
Duration of effect
Daily dosing; benefits build over weeks (plasma half-life: ~30-70 minutes)
See full half-life table →Key Features
- Maximum GH boost
- Synergistic effects
- Enhanced IGF-1
- Muscle & recovery
Includes key details, half-life data, usage notes and research sources.
Usage Instructions
Subcutaneous injection as recommended. Consult a healthcare professional for protocols tailored to your goals.
Research Highlights
- Backed by scientific research
- Manufactured to pharmaceutical standards
- Used in clinical research settings
- Established safety profile
Safety Information
- •Consult your healthcare provider before use
- •Not intended for pregnant or nursing women
- •Store properly according to instructions
- •Report any adverse effects to your healthcare provider
Source: Journal of Clinical Endocrinology & Metabolism
Clinical Research
The CJC-1295 and Hexarelin combination increased IGF-1 levels by 78% and GH secretion by 5-10x, producing the most potent GH+IGF1 boost among peptide combinations.
Read full studyAdditional Research
Source: García-del-Barco-Herrera et al., Clin Med Insights Cardiol (2017)
Comprehensive open-access review of the GHRP + GHRH-analogue combination strategy summarising the synergy that underpins all 'overload' protocols — including reproducible human GH/IGF-1 elevation and cardiac cytoprotection data.
Read full studyHuman Clinical Trials
- CJC-1295 in healthy adultsJournal of Clinical Endocrinology & Metabolism · 2006
Two randomised placebo-controlled ascending-dose trials: sustained increases in growth hormone and IGF-1.
Read the trial - Hexarelin dose-response studyEuropean Journal of Clinical Pharmacology · 1994
Double-blind placebo-controlled rising-dose study in humans: dose-dependent growth hormone release.
Read the trial12participants